Review
doi: 10.1111/j.1748-1716.2008.01936.x.
Epub 2008 Nov 15.
Connective tissue growth factor and cardiac fibrosis
Affiliations
- PMID: 19040711
- DOI: 10.1111/j.1748-1716.2008.01936.x
Item in Clipboard
Review
Connective tissue growth factor and cardiac fibrosis
Acta Physiol (Oxf).
2009 Mar.
Abstract
Cardiac fibrosis is a major pathogenic factor in a variety of cardiovascular diseases and refers to an excessive deposition of extracellular matrix components in the heart, which leads to cardiac dysfunction and eventually overt heart failure. Evidence is accumulating for a crucial role of connective tissue growth factor (CTGF) in fibrotic processes in several tissues including the heart. CTGF orchestrates the actions of important local factors evoking cardiac fibrosis. The central role of CTGF as a matricellular protein modulating the fibrotic process in cardiac remodelling makes it a possible biomarker for cardiac fibrosis and a potential candidate for therapeutic intervention to mitigate fibrosis in the heart.
Similar articles
-
Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v8-9. doi: 10.1093/rheumatology/ken278. Rheumatology (Oxford). 2008. PMID: 18784153 Review.
-
[Connective tissue growth factor (CTGF): a key factor in the onset and progression of kidney damage].Nefrologia. 2009;29(5):382-91. doi: 10.3265/Nefrologia.2009.29.5.5429.en.full. Nefrologia. 2009. PMID: 19820749 Review. Spanish.
-
Expression of connective tissue growth factor in acute heart allograft rejection in rats.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008 May;33(5):425-31. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008. PMID: 18544847
-
Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases.Liver Int. 2008 Sep;28(8):1065-79. doi: 10.1111/j.1478-3231.2008.01826.x. Liver Int. 2008. PMID: 18783549 Review.
-
Cardiac tissue factor: roles in physiology and fibrosis.Clin Exp Pharmacol Physiol. 2008 Mar;35(3):342-8. doi: 10.1111/j.1440-1681.2007.04872.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18290875 Review.
Cited by
-
A Review of Therapeutic Strategies against Cardiac Fibrosis: From Classical Pharmacology to Novel Molecular, Epigenetic, and Biotechnological Approaches.Rev Cardiovasc Med. 2023 Aug 8;24(8):226. doi: 10.31083/j.rcm2408226. eCollection 2023 Aug. Rev Cardiovasc Med. 2023. PMID: 39076707 Free PMC article. Review.
-
Achievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload-induced cardiac hypertrophy and fibrosis.Exp Ther Med. 2016 Oct;12(4):2027-2038. doi: 10.3892/etm.2016.3570. Epub 2016 Aug 4. Exp Ther Med. 2016. PMID: 27698689 Free PMC article.
-
Connective Tissue Growth Factor Is Related to All-cause Mortality in Hemodialysis Patients and Is Lowered by On-line Hemodiafiltration: Results from the Convective Transport Study.Toxins (Basel). 2019 May 13;11(5):268. doi: 10.3390/toxins11050268. Toxins (Basel). 2019. PMID: 31086050 Free PMC article. Clinical Trial.
-
Myofibroblast Ccn3 is regulated by Yap and Wwtr1 and contributes to adverse cardiac outcomes.Front Cardiovasc Med. 2023 Mar 14;10:1142612. doi: 10.3389/fcvm.2023.1142612. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36998974 Free PMC article.
-
Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort.Diabetes Care. 2018 Apr;41(4):840-846. doi: 10.2337/dc17-2083. Epub 2018 Jan 30. Diabetes Care. 2018. PMID: 29382658 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
